BioCentury
ARTICLE | Clinical News

FPA144: Phase I started

January 5, 2015 8:00 AM UTC

Five Prime began a 2-part, open-label, U.S. Phase I trial to evaluate IV FPA144 every 2 weeks in about 100 patients. The dose-escalation part will enroll about 30 patients with solid tumors, and the d...